S&P 500 7718.60 -0.38%
NASDAQ 26506.99 -0.29%
TASI 11024.73 -0.40%
Oil (WTI) 91.48 +0.00%
Oil (Brent) 96.28 +0.00%
VIX 15.30 +5.30%
Gold 4476.60 +0.00%
USD/SAR 3.76 +0.02%

Vertex Pharmaceuticals Incorporated

VRTX · Healthcare · · USD
546.12 USD
0.00 (-2.12%)
● Updated 2026-09-07 21:04 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Short-term (Swing)

76
/ 100
Technical 75
Trend & RS 91
Momentum 77
Fundamental (0%) 89
Macro 64
Liquidity 47
ComponentScoreWeight
Technical 75.0 40%
Trend & RS 91.1 20%
Momentum 77.1 20%
Fundamental 88.9 0%
Macro 64.4 15%
Liquidity 46.9 5%

Trade Setup

Entry 546.12
Stop Loss 520.04 (4.8%)
Target 1 (1:1) 572.20 (+4.8%)
Target 2 (2:1) 598.28 (+9.6%)
ATR(14) 13.04 (2.4%)
Risk per Share 26.08
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 29.3 -0.83
Momentum 77.1 +1.08
Quality 77.9 +1.12
Composite 61.4

Quality Scores

Piotroski F-Score 7 /9 — Strong
✓ ✓ ✗ ✗ ✓ ✓ ✓ ✓ ✓
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score 44.13 — Safe Zone
Distress <1.81Grey 1.81–2.99>2.99 Safe

Valuation vs Peers Overvalued

MetricStockSectorvs Peers
P/E Ratio 31.8 22.0 +45% above
P/B Ratio 6.8 4.0 Above

Comparing against Healthcare median multiples.

Trading at a premium to sector peers — verify growth justifies premium.

Intrinsic Value (DCF) Significantly Overvalued

Intrinsic Value
328.89
vs
Market Price
546.12
Upside
-39.8%
Margin of Safety -66.0%
Stage 1 PV (5yr FCF)19,135,813,287
Terminal Value PV64,225,243,043
Total Enterprise Value83,361,056,330

Assumptions

Base FCF3,477,483,877
Growth Rate (5yr)12.5%
Terminal Growth2.5%
Discount Rate (WACC)9.0%

2-stage DCF: 5yr projected FCF + Gordon Growth terminal value. Estimates only — adjust growth and WACC for your own assumptions.

Position Sizing — Kelly Criterion

4.5%
Recommended Size
49.03%
Full Kelly
24.51%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 76/100. Estimated win rate 63%, avg win 9.5%, avg loss 3.5%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

BEAR Regime: BEAR (20% confidence) — position size reduced 10%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
59.36
RSI(14)
14.7567
MACD

Relative Strength (RS) IMPROVING

77
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY ↑ RISING (+17.5% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (2d since high)
Sector Outperformance +14.5% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
IMPROVING: Gaining momentum — the stock is starting to outperform the market. Watch for RS new high confirmation.

Technical Indicators

IndicatorValueSignal
Rsi 59.36 NEUTRAL
Macd 14.7567 BEARISH
Ma Cross 508.76 / 466.15 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.72x NORMAL

Key Levels

LevelPrice
52-Week High560.25
Bollinger Upper568.76
SMA(200)466.15
SMA(50)508.76
SMA(20)538.78
Current Price546.12
Bollinger Lower508.79
52-Week Low374.17
ATR(14)13.04

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

MARKUP Confidence
100%
Acc: 0.0  |  Dist: 0.0  |  Markup: 2.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-08-31 Normal 1.07x Normal bar — no special VSA pattern
2026-09-01 Normal 0.66x Normal bar — no special VSA pattern
2026-09-02 Normal 1.55x Normal bar — no special VSA pattern
2026-09-03 Normal 0.72x Normal bar — no special VSA pattern
2026-09-04 Normal 0.72x Normal bar — no special VSA pattern

Ichimoku Cloud BULLISH

LineValueStatus
Tenkan-sen (9) 546.24 Above Kijun
Kijun-sen (26) 512.88 Base line
Senkou A 529.56 Leading span A
Senkou B 512.62 Leading span B
Cloud 512.62 – 529.56 Bullish (Green)
Price vs Cloud 546.12 Above Cloud
Chikou Span 477.10 Bullish
Alignment Score 4/4 BULLISH

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BULLISH FADING
BB: 508.79 – 568.76  |  KC: 517.13 – 560.43

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Regular Bearish RSI 9
Regular Bearish RSI 13
Regular Bearish MACD 13

Anchored VWAP

VWAP: 457.82 Anchor: 2025-09-24 (52w Low) ABOVE AVWAP +19.3%

Heikin-Ashi Trend

WEAKLY BEARISH Full data via /api/advanced/VRTX

Valuation

MetricValue
Market Cap138.42B
P/E (TTM)31.84
Forward P/EN/A
P/B6.83
EPS17.15

Financial Health

MetricValue
Revenue Growth12.5%
Profit Margin35.0%
ROE23.5%
Debt/Equity9.77
Current Ratio3.19
Dividend YieldN/A
Payout RatioN/A
Beta0.32

Trading Data

546.12
Open
546.12
Day High
546.12
Day Low
803.5K
Volume (0.5x avg)

Recent News (8)

IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
24/7 Wall St. · 2026-09-07
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
Motley Fool · 2026-09-04
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
Motley Fool · 2026-09-02
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?
Barchart · 2026-09-02
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Zacks · 2026-09-02
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks
Simply Wall St. · 2026-09-02
Goldman Sachs refreshes conviction lists on both sides of the Atlantic
Investing.com · 2026-09-01
Vertex Pharmaceuticals (VRTX) Could Be 3% Undervalued If Its Pipeline Growth Holds
Simply Wall St. · 2026-09-01

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —